The content on this page and other TGA archive pages is provided to assist research and may contain references to activities or policies that have no current application. See the full archive disclaimer.
NDPSC record of reasons, 45th meeting, 11-13 October 2005
National Drugs and Poisons Schedule Committee
The Record of the Reasons contains the basis of scheduling decisions and other outcomes arising from the meeting. Please note that the Record of the Reasons includes extracts from the NDPSC minutes which have been edited to remove confidential information.
*Large file warning: Attempting to open large pdf files over the Internet within the browser window may cause problems. It is strongly recommended you download this document to your own computer and open from there.
NDPSC Record of reasons, Meeting 45 (pdf,525kb)
Contents
Glossary
- 1.8 NDPSC working parties
- 1.8.1 Trans-Tasman Harmonisation Working Party
- 1.8.1.1 Harmonisation of Medicines and the OZNZ Scheduling Database
- 1.8.1 Trans-Tasman Harmonisation Working Party
2. Proposed changes/additions to Parts 1 to 3 and Part 5 of the Standard for the Uniform Scheduling of Drugs and Poisons
- 2.1 SUSDP, Part 1
- 2.1.1 Interpretation - "Dermal Use"
- 2.1.2 Definition of Compounded
Agricultural/Veterinary, Industrial and Domestic Chemicals
3. Matters arising from the minutes of the previous meeting
- 3.1 Storage statement for Schedule 5 and Schedule 6 products
4. Other outstanding matters from previous meetings
- 4.1 Praziquantel
- 4.2 Alkaline salts
- 4.3 Paraquat
6. Matters referred by the Australian Pesticides and Veterinary Medicines Authority
- 6.1 Methyleugenol
- 6.2 Iodomethane
- 6.3 Fatty Acids (oleic acid, palmitic acid, steric acid, linoleic acid, lauric acid, mysteric acid, pentadecanoic acid, azelaic acid, pimelic acid) and their methyl esters
- 6.4 Chlorhexidine
7. Matters referred by Office of Chemical Safety (OCS) Branch
- 7.1 Chlorfluazuron
- 7.2 Termite barriers
- 7.3 Formothion
Pharmaceuticals
12. Matters arising from the minutes of the previous meeting
- 12.1 Pseudoephedrine
- 12.2 Pomegranate (punica granatum)
- 12.3 Jalap resin
- 12.4 Copaiba Balsam
13. Other outstanding matters from previous meetings
- 13.1 Oseltamivir
- 13.2 Miconazole
- 13.3 Amisulpride
- 13.4 Phenylephrine
- 13.5 Required advisory statements for medicine labels
- 13.6 Blood products
- 13.6.1 Octocog alfa (RCH)
- 13.7 Prochlorperazine
- 13.8 Piper methysticum (KAVA)
- 13.9 Pantoprazole
- 13.10 Orlistat
14. Proposed changes/additions to the Standard for the Uniform Scheduling of Drugs and Poisons
- 14.1 SUSDP, Part 4
- 14.1.1 Hydrocortisone and hydrocortisone acetate
- 14.2 SUSDP, Part 5
- 14.2.1 Cetirizine (Appendix F and Appendix K)
- 14.2.2 Item deleted
- 14.2.3 Clioquinol (Appendix C)
15. Matters referred by the Australian Drug Evaluation Committee (ADEC)
- 15.1 New substances (not seen before by the NDPSC)
- 15.1.1 Human plasma-derived protein C
- 15.1.2 Eplerenone
- 15.1.3 Strontium ranelate
- 15.1.4 Sevelamer hydrochloride
16. Other matters for consideration
- 16.1 Item deleted
- 16.2 N,N-dimethylamphetamine
- 16.3 Sedating antihistamines
- 16.4 Potassium chloride
18. Matters referred by the medicines classification committee (MCC) of New Zealand
- 18.1 Minutes of the November 2004 and June 2005 MCC meetings
20. Matters referred by the Medical Devices Evaluation Committee (MDEC)
21-23. Items deleted
24. Amendments to the SUSDP
- 24.1 Editorial changes and errata
| Attachment | Size |
|---|---|
 NDPSC Record of Reasons October 2005 meeting (pdf) | 524KB |